33 results
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
11 May 23
Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022
4:06pm
the value of ZYNRELEF through a broader and deeper penetration of accounts; second, to address application issues through training and expanded indications
8-K
1h9iaw318i8hhm
24 Sep 21
Departure of Directors or Certain Officers
8:30am
8-K
EX-99.1
h7ssc72a
13 May 21
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
8:25am
8-K
EX-99.2
b1elh8e3y5dak0
11 Jan 21
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program
8:40am
8-K
EX-99.2
zhd0w
7 Jan 19
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
8:36am